Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].

Annales de pathologie - 1 Jan 2016

Hamard Cécile, Ruppert Anne-Marie, Lavole Armelle, Rozensztajn Nathalie, Antoine Martine, Cadranel Jacques, Wislez Marie

Abstract excerpt

Recently, developments of therapies that target abnormally activated signaling pathways are increasing for patients with non-small cell lung cancer. EGFR mutations are found in about 10% of lung cancers, especially in adenocarcinoma, women and non-smokers. Three EGFR inhibitors (erlotinib, gefitinib and afatinib) received a European marketing authorization for up to first line treatment of EGFR mutated NSCLC....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Genes, Neoplasm

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Neoplasm Proteins

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 26775573
DOI: 10.1016/j.annpat.2015.11.002

Genes

EGFR
ALK
BRAF
EML4
KRAS
MET
ROS1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].PMID 26775573Read ↗

[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments].Semantic proximity Read ↗

[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].Semantic proximity Read ↗

[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].Semantic proximity Read ↗

Targeted therapies and immunotherapy in non-small-cell lung cancerSemantic proximity Read ↗

[Targeted therapies and non-small cell carcinomas : novelties].Semantic proximity Read ↗

Targeted therapy of non-small cell lung cancer.Semantic proximity Read ↗

[New targets and new drugs in thoracic oncology].Semantic proximity Read ↗

Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers.Semantic proximity Read ↗

[Current Status and Future Perspectives of Molecular Targeted Therapies for Lung Cancer].Semantic proximity Read ↗

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeted therapy for non-small-cell lung cancer: past, present and future.Semantic proximity Read ↗

Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.